If you have been given an outpatient appointment at the hospitals and are unable to attend for whatever reason you can use the form below.
It is really important that you let us know of any changes as soon as possible. This means we can offer the original appointment to another patient.
Please complete the form below with your contact details and as much information as possible. You can find most of the information we need on your appointment letter.
If you have any problems using this form, please call the number on your appointment letter and we will do our best to help you. You will receive a response from us so you know it has been received and actioned.
If you wish to change the date and time of your appointment you, you can click the re-book option and state any dates that are not suitable for you, or you can contact us using the number on your appointment letter.
Dr Salih is the lead consultant for Rheumatology research with commercial and academic studies in Rheumatoid Arthritis, Ankylosing Spondylitis, Giant Cell Arteritis , Sjogrens and Systemic Lupus Erythematosus.
Please contact the research nurses on 01925 662946 or email WHH.Research@nhs.net if you would like any more information about research studies in Rheumatology.
Please contact the research nurses on 01925 662946 if you would like any more information about research studies in Orthopaedics.
Using DNA from blood and clinical information, we can look at similarities and differences between people with SLE and those unaffected by the disease.
These may help to identify genetic differences that are more common in SLE patients and then ask how these genetic factors affect the immune system and how they influence the nature and severity of the disease.
This study involves a one off consent, blood sample, patient questionnaire and data collection from patient notes that can be done as part of your out-patient clinic visit.
Run by the University of Leeds, the purpose of the study is to find out more about the causes of giant cell arteritis (GCA, sometimes called temporal arteritis) and polymyalgia rheumatica (PMR).
We would also like to find out how to predict whether a person with one of these conditions will be more severely affected or only mildly affected.
The study involves a blood sample, patient questionnaire and data collection from hospital notes.
We hope that the findings of this research will help other patients with this condition in the future by leading to the development of better treatments for this disease, with fewer side-effects than the steroid treatment that is currently standard.
The British Society for Rheumatology Biologics Register in Rheumatoid Arthritis (BSRBR-RA) tracks the progress of people with rheumatoid arthritis (RA) who have been prescribed biologic (including biosimilar) drugs
The British Society for Rheumatology Biologics Register in Rheumatoid Arthritis (BSRBR-RA) tracks the progress of people with rheumatoid arthritis (RA) who have been prescribed biologic (including biosimilar) drugs in the UK to monitor the long-term safety of these drugs.
It is one of the largest prospective studies of patients receiving these drugs in the world with over 20,000 patients registered in the study since it started in 2001.
At regular time points, data will be collected by research nurses from patient notes and patients will complete postal questionnaires.
Find out more on their website here.
We also have several clinical trials sponsored by pharmaceutical companies. These are looking at new treatments or comparing new treatments with established ones for several rheumatological conditions.
Your clinician or nurse specialist may ask one of the research nurses to speak to you about these if they feel it may be appropriate for you to consider taking part.
There are several studies in current setup and we will publish shortly.
A research study to identify the key genetic effects of ANKYLOSING SPONDYLITIS
The British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS)
Mr Stables is the principal investigator involved in national multicentre orthopaedic studies here at Warrington & Halton.
The specialities currently covered are:
Platelet Rich Plasma in Achilles Tendon Healing - A study looking at the best way to heal your torn Achilles tendon
The PATH-2 Study compares usual non-surgical plaster cast treatment for a torn Achilles tendon to a new treatment in which Platelet Rich Plasma (PRP) is injected into the torn tendon, in addition to receiving usual cast treatment. The aim is to see if PRP improves healing.
A new treatment has been developed, using an injection of ‘Platelet Rich Plasma’ (PRP). The aim of PRP is to improve the repair of the tendon. PRP aims to take advantage of the body’s normal healing abilities to help repair injuries. The cells in PRP contain special growth and regeneration factors that stimulate the body’s healing response in the injured tendon.
PRP is made using a sample of a person’s own blood. The blood sample is taken using a needle and syringe. The blood is spun in a machine called a centrifuge and after spinning what remains is the platelet rich plasma.
The person’s own PRP is then injected into their Achilles tendon at the site if the injury. A local anaesthetic is given at the tendon area before the PRP injection to help ease any discomfort.
The PRP injection is applied immediately prior to the cast, splint or boot.
PRP has been shown to accelerate healing in a small group of patients. A larger study (the PATH-2 Study), is now underway to look into this further to improve the evidence as to whether this is an effective treatment.